SynthesisFrontiers in medicine2026
Sarcopenia and outcomes after revascularization for peripheral arterial disease: a scoping review.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Sarcopenia, a degenerative skeletal muscle disease associated with aging and chronic diseases, is a recognized risk factor for poor postoperative outcomes in various surgical fields. However, in patients with peripheral artery disease (PAD) undergoing revascularization, systematic evidence on its epidemiology, assessment practices, and prognostic impact is lacking. This scoping review aims to synthesize available evidence to clarify the prevalence, diagnostic methods, and association between sarcopenia and adverse postoperative outcomes in patients with PAD, thereby informing perioperative risk stratification and targeted interventions. Methods: This study was conducted following the Arksey & O'Malley scoping review framework and the Joanna Briggs Institute (JBI) revised scoping review methodology. Relevant studies were retrieved from PubMed, Embase, Web of Science, Cochrane Library, CNKI, WanFang Data, and VIP Chinese Science and Technology Journal Database from inception to June 30, 2025. Eligible studies were published in Chinese or English and focused on the impact of sarcopenia on the prognosis of patients with PAD. The extracted data were collated, categorized, and summarized. Results: Twelve studies were included. The prevalence of sarcopenia in patients with PAD ranged from 9.01% to 66.67%. Most existing studies diagnosed sarcopenia solely based on imaging-derived muscle parameters without comprehensive assessment of muscle strength and physical function. Despite these methodological limitations, imaging-evident muscle loss was correlated with elevated postoperative mortality, increased risk of cardiovascular events, and poor limb prognosis in patients with PAD. Conclusions: Sarcopenia is prevalent among patients with PAD and serves as a potential risk factor for adverse postoperative outcomes. Inconsistent diagnostic criteria and substantial methodological heterogeneity across current studies restrict the generalizability of available evidence. Future efforts are required to establish a standardized, multidimensional assessment system for sarcopenia, and high-quality prospective studies are needed to clarify its perioperative prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.